BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cellzome AG Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway


9/17/2009 10:07:41 AM

HEIDELBERG, Germany, September 16 /PRNewswire/ --

- Integrated Chemical Genetics and Proteomics Approach Identifies new Potential Drug Targets in Wnt Pathway

Cellzome announces today, the publication entitled "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling"** is now available online in Nature.

The paper describes how Cellzome's quantitative chemical proteomics platform was used to identify a small molecule which plays a critical role in the regulation of the Wnt pathway. The small molecule stabilizes axin by inhibiting the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2. Both tankyrase isoforms interact with a highly conserved domain of axin and stimulate its degradation through the ubiquitin-proteasome pathway. Thus, the study provides new mechanistic insights into the regulation of axin protein homeostasis and presents new avenues for therapeutic intervention in this key cancer pathway. This transforming science was conducted as part of the collaboration between Cellzome and Novartis Institutes for Biomedical Research (NIBR).

Dr. David Simmons, CSO of Cellzome, said: "This paper shows the powerful insights provided by Cellzome's proprietary chemical proteomics technology platform. Our platform also includes Kinobeads(TM) which we use for the discovery and development of a new generation of kinase inhibitors and Episphere(TM) for the discovery of novel drug candidates for epigenetic targets."

** Huang, S., et.al. "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling", Nature, 10.1038/nature08356, 2009.

About Cellzome Inc.

Cellzome is a privately-owned drug discovery and development company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a proprietary technology for the screening and profiling of kinase inhibitors in physiologically-relevant cells and tissues. The most advanced program, targeting PI3K(gamma), is anticipated to enter the clinic in 2010, and several other programs are in early preclinical testing.

Cellzome is expanding its distinctive technology, in a novel form called Episphere(TM), to the discovery and development of novel drug candidates for epigenetic targets in their protein complexes.

Cellzome has significant collaborations with GSK and Johnson & Johnson. Its holding company is domiciled in the US and it employs about 90 people at its two laboratories in Cambridge, UK and Heidelberg, Germany.

SOURCE Cellzome Inc.

CONTACT: For more information please contact: Cellzome: Dr. David Simmons,
Chief Scientific Officer, Tel: +44(0)1799-532-820, press@cellzome.com.
Media contact: Hogarth Partnership, Sarah MacLeod, Tel: +44(0)207-357-9477.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES